DiaMedica Therapeutics to Present at Four September Conferences
Event summary
- DiaMedica Therapeutics (Nasdaq: DMAC) will participate in four investor conferences in September 2026.
- CEO Rick Pauls and CMO Dr. Julie Krop will hold a fireside chat at the Cantor Global Healthcare Conference on September 11.
- Rick Pauls will present at the HC Wainwright Global Investment Conference on September 15.
- The company is developing DM199, a recombinant KLK1 protein, for preeclampsia, fetal growth restriction, and acute ischemic stroke.
The big picture
DiaMedica's participation in multiple investor conferences suggests a push to increase visibility ahead of potential clinical milestones. The focus on preeclampsia and acute ischemic stroke aligns with growing interest in novel treatments for vascular diseases. The company's strategy hinges on leveraging its lead candidate, DM199, to secure partnerships or funding.
What we're watching
- Clinical Progress
- How DiaMedica's updates on DM199's development will impact investor sentiment.
- Market Positioning
- Whether the company can differentiate itself in the competitive acute ischemic stroke treatment space.
- Funding Strategy
- The pace at which DiaMedica advances toward potential partnerships or financing rounds.
Related topics